Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260303 | 0.98 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL2260433 | 0.96 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL2261442 | 0.95 | MCHR1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL2260449 | 0.81 | NPC1 (0.57) | NPC1RAB9AHPGDKMT2AERN1 | |
| SCHEMBL200711 | 0.79 | ADORA1 (0.51) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL201497 | 0.79 | ADORA1 (0.49) | NPC1RAB9ASMN1; SMN2MCHR1KMT2A | |
| SCHEMBL2261354 | 0.77 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL2262131 | 0.77 | RAB9A (0.60) | NPC1RAB9ASMN1; SMN2HPGDTP53 | |
| SCHEMBL2260576 | 0.77 | CHEK2 (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8037431 | 0.77 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989454-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2234995-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| WO-2009077385-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | NPC1 689/4885RAB9A 3108/4885SMN1; SMN2 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.